Overview
From Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity.
Drs. Kenneth B. Gordon and Alexis Ogdie-Beatty facilitate a critical review and discuss up-to-date data impacting psoriasis and psoriatic arthritis (PsA) at the point of care. Areas of discussion include:
• Joint manifestations and key clinical features of psoriasis that may be indicative of progression to PsA
• New and emerging psoriasis/PsA therapies and how they intersect with clinical practice guidelines
• Diagnostic and treatment delays in PsA and how to reduce time to treatment
• Case-based discussions on diverse patients with psoriasis and PsA
Editor’s Note: Since the recording/publication of this enduring activity, the FDA has issued two new indication approvals for therapies discussed in the activity, as follows:
• ixekizumab is now FDA-approved for both psoriasis and PsA;
• guselkumab is now FDA-approved for psoriasis.
• Joint manifestations and key clinical features of psoriasis that may be indicative of progression to PsA
• New and emerging psoriasis/PsA therapies and how they intersect with clinical practice guidelines
• Diagnostic and treatment delays in PsA and how to reduce time to treatment
• Case-based discussions on diverse patients with psoriasis and PsA
Editor’s Note: Since the recording/publication of this enduring activity, the FDA has issued two new indication approvals for therapies discussed in the activity, as follows:
• ixekizumab is now FDA-approved for both psoriasis and PsA;
• guselkumab is now FDA-approved for psoriasis.
This activity is intended for dermatologists, rheumatologists, primary care physicians, nurse practitioners, pharmacists, and other affiliated providers involved in the diagnosis and treatment of patients with psoriasis and psoriatic arthritis.
Several therapies with differing mechanisms of action, efficacy, safety, and routes of administration are available for the treatment of psoriasis and PsA. Clinicians require an understanding of the impacts of failure to aggressively manage patients and consider individual patient characteristics and preferences when prescribing therapy. The increasing availability of new therapies in the absence of head-to-head clinical trials and practical guidance raises questions on the role of novel therapies in current treatment paradigms, and whether it is possible to identify which patients will elicit a response to a given target across the disease course and severity. As current data has implications for possible application in the treatment of psoriasis and PsA, it behooves clinicians to stay abreast of ongoing research into emerging therapies.
Upon completion of this activity, participants will be able to:
• Outline the immunologic pathways that contribute to the skin and joint manifestations of psoriasis and psoriatic arthritis
• Compare and contrast available therapies, their targets, and clinical application
• Discuss patient-specific factors that may inform selection of therapy across the disease course to ensure response
• Critically assess the mechanisms of action, efficacy, and safety of emerging therapies for psoriasis and psoriatic arthritis
• Outline the immunologic pathways that contribute to the skin and joint manifestations of psoriasis and psoriatic arthritis
• Compare and contrast available therapies, their targets, and clinical application
• Discuss patient-specific factors that may inform selection of therapy across the disease course to ensure response
• Critically assess the mechanisms of action, efficacy, and safety of emerging therapies for psoriasis and psoriatic arthritis
Jointly sponsored by Purdue University College of Pharmacy and the Academy for Continued Healthcare Learning (ACHL).
Supported by educational grants from Celgene Corporation, Janssen Biotech, Inc., and Novartis Pharmaceuticals Corporation.
This site is best viewed with an HTML5 compatible browser; this list includes the versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentations, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
Select images in this activity (c) 2017 American College of Rheumatology. Used with permission.
Apply to bring this activity to your institution - it's FREE! Visit http://www.achlvpp.org/psoriasis/.
Expert faculty will travel to present to your clinical team in-person.
CME/CPE credit available for physicians and pharmacists.
Expert faculty will travel to present to your clinical team in-person.
CME/CPE credit available for physicians and pharmacists.
Kenneth B. Gordon, MD
Thomas J. Russell Family/Milwaukee Dermatologists Professor and Chair
Department of Dermatology
Medical College of Wisconsin
Milwaukee, WI
Thomas J. Russell Family/Milwaukee Dermatologists Professor and Chair
Department of Dermatology
Medical College of Wisconsin
Milwaukee, WI
Alexis Ogdie-Beatty, MD, MSCE
Assistant Professor of Medicine and Epidemiology
Director, Penn Psoriatic Arthritis Clinic
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
ACHL and Purdue University College of Pharmacy require that the faculty participating in a CME/CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this activity.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Cyclosporine for psoriatic arthritis; FDA-approved for psoriasis; methotrexate, sulfasalazine, and leflunomide are also not approved for PsA but are commonly used drugs and included in all treatment guidelines
The following financial relationships have been provided:
Kenneth B. Gordon, MD
Consultant: AbbVie Inc., Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Janssen Biotech, Inc., Novartis Pharmaceuticals Corporation
Grants/Research Support: AbbVie Inc., Amgen Inc., Boehringer Ingelheim, Celgene Corporation, Demira, Inc., Eli Lilly and Company, Janssen Biotech, Inc., Novartis Pharmaceuticals Corporation, Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc.
Alexis Ogdie-Beatty, MD, MSCE
Advisory Board Membership: Novartis Pharmaceuticals Corporation, Pfizer, Inc., Takeda Pharmaceuticals U.S.A., Inc.
Consultant: Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Grants/Research Support: Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Cyclosporine for psoriatic arthritis; FDA-approved for psoriasis; methotrexate, sulfasalazine, and leflunomide are also not approved for PsA but are commonly used drugs and included in all treatment guidelines
ACHL and Purdue University College of Pharmacy staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education/continuing pharmacy education (CME/CPE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CPE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CPE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and Purdue University College of Pharmacy require their speakers to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online activity, and complete the post-test and evaluation. To receive credit, 66% or greater must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
CPE credit will be added to CPE Monitor the 1st of every month.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Purdue University College of Pharmacy is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-17-065-H01-P, 1.0 contact hours (.10 CEU).
